Interferon die Aktie 2004..........Volumen steigt.......IFSC lebt wieder - 500 Beiträge pro Seite
eröffnet am 01.03.04 20:52:55 von
neuester Beitrag 14.03.04 11:04:32 von
neuester Beitrag 14.03.04 11:04:32 von
Beiträge: 15
ID: 828.615
ID: 828.615
Aufrufe heute: 0
Gesamt: 4.865
Gesamt: 4.865
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 24 Minuten | 6031 | |
| vor 13 Minuten | 5237 | |
| vor 12 Minuten | 3022 | |
| vor 1 Stunde | 2106 | |
| vor 23 Minuten | 1605 | |
| heute 13:32 | 1462 | |
| heute 06:53 | 1391 | |
| vor 6 Minuten | 1348 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.364,58 | +0,81 | 267 | |||
| 2. | 3. | 171,64 | +0,02 | 80 | |||
| 3. | 2. | 10,320 | -2,46 | 75 | |||
| 4. | 4. | 1,1200 | -12,50 | 59 | |||
| 5. | 13. | 0,1995 | +3,64 | 51 | |||
| 6. | Neu! | 6,1720 | -0,29 | 47 | |||
| 7. | 6. | 7,0280 | +1,56 | 46 | |||
| 8. | 18. | 10,100 | -7,00 | 41 |
Feedback
IFSC on Pink Sheets.............
Nur noch 5 Handelstage danach geht die Party ab.
Alle Infos unter WKN: 918064 oder schaut doch mal unter HEB nach...
Kleiner Tipp......Börsenkapitalisierung ein Witz...
Da geht noch was....
Heute wieder 100K
Grüsse
Nur noch 5 Handelstage danach geht die Party ab.
Alle Infos unter WKN: 918064 oder schaut doch mal unter HEB nach...
Kleiner Tipp......Börsenkapitalisierung ein Witz...
Da geht noch was....
Heute wieder 100K
Grüsse
@ Tornado
Long, long and strong!!
Wo sollen wir denn, nach einem erfolgten Hype, die Interferon-Party zelebrieren?
Rio, Monte, SF...
, wenn schon - denn schon...
Sieht verdammt gut aus!
cu and good luck
POLYHAWK
Long, long and strong!!
Wo sollen wir denn, nach einem erfolgten Hype, die Interferon-Party zelebrieren?
Rio, Monte, SF...
, wenn schon - denn schon...Sieht verdammt gut aus!
cu and good luck
POLYHAWK
Du könntest recht haben mit long.......
Hemispherx Biopharma Announces FDA Authorization for a Clinical Study with New Biological Alferon LDO for HIV; Company to Initiate Phase II Study in Early-Stage HIV Patients
E-mail or Print this story
2 March 2004, 10:00am ET
PHILADELPHIA--(BUSINESS WIRE)--March 2, 2004--Hemispherx Biopharma, Inc. (AMEX:HEB) today announced the authorization by the U.S. Food and Drug Administration (FDA) to conduct a clinical trial with Alferon LDO(R) in HIV-infected patients. The submission to the Investigational New Drug Application (IND) for "Human Leukocyte Interferon (Alferon N), Oral," ref. BB-IND 3534, allows the Company to initiate a Phase II study of Alferon LDO(R), Low Dose Oral natural alpha interferon, in HIV positive subjects in early stage of disease. The Company expects to initiate the clinical trial in the coming weeks. The trial may be expanded into other life threatening viral diseases.
The objective of the randomized dose-ranging study is to evaluate the safety and activity of orally administered low dose interferon alpha-n3 as an immunomodulator in subjects with asymptomatic HIV-1 infection. The primary endpoints of the study will include an increase or upregulation in genes known to be mediators of the natural immune response using cutting edge gene chip technology. Secondary endpoints will include the absolute CD4 count and plasma HIV RNA levels.
In December 2003 the Company announced its manufacturing agreement with Aplicare for Alferon LDO(R). To date, over 100,000 sachets of Alferon LDO(R) are available for use in the study.
Study Design
The study will be an open-label, randomized outpatient study in asymptomatic HIV infected subjects using a range of doses of interferon. Patients will be randomized to receive Alferon LDO(R) in a buffer solution once each day for 10 consecutive days at different doses. The subjects will be randomly assigned to each dose level. Clinical symptoms and adverse events will be evaluated and gene chip microarray analysis evaluations will be made in conjunction with laboratories at Vanderbilt University. The overall duration of the study, in which 60 patients are to be enrolled, will be 6 weeks.
About Alferon LDO and Potential Public Health Enhancement in
Developing Nations
Oral interferon is an experimental immunotherapeutic believed to work by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster an immune response through the entire body orally. Oral interferon would be much more economically feasible for patients and logistically manageable in development programs in third-world countries primarily affected by the this and other emerging viruses (SARS, Ebola, bird flu, etc.). Oral administration of Alferon N(R), with its affordability, low toxicity, no production of antibodies, and broad range of potential bio activity, could be a breakthrough treatment for viral diseases.
About Hemispherx and Public Health
Mentioned Last Change
HEB 3.99 0.09dollars or (2.30%)
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon N(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N(R)) and GMP certified manufacturing facilities for its novel pharma products. Hemispherx is committed to clinical development in developing nations. This commitment stems from the vast market size of the untreated patient (approx. 35 Million) and the unique biochemical property (in vitro studies) of Alferon N(R), making this high potency product worthy of this study. A number of the in vitro potency studies have been conducted at Walter Reed National Army Medical Center and published in peer reviewed medical literature. For more information please visit www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R) and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications including SARS. The Alferon(R) asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.
CONTACT: Hemispherx
Investor Relations:
Dianne Will, 518-398-6222
ir@hemispherx.net
www.hemispherx.net
Hemispherx Biopharma Announces FDA Authorization for a Clinical Study with New Biological Alferon LDO for HIV; Company to Initiate Phase II Study in Early-Stage HIV Patients
E-mail or Print this story
2 March 2004, 10:00am ET
PHILADELPHIA--(BUSINESS WIRE)--March 2, 2004--Hemispherx Biopharma, Inc. (AMEX:HEB) today announced the authorization by the U.S. Food and Drug Administration (FDA) to conduct a clinical trial with Alferon LDO(R) in HIV-infected patients. The submission to the Investigational New Drug Application (IND) for "Human Leukocyte Interferon (Alferon N), Oral," ref. BB-IND 3534, allows the Company to initiate a Phase II study of Alferon LDO(R), Low Dose Oral natural alpha interferon, in HIV positive subjects in early stage of disease. The Company expects to initiate the clinical trial in the coming weeks. The trial may be expanded into other life threatening viral diseases.
The objective of the randomized dose-ranging study is to evaluate the safety and activity of orally administered low dose interferon alpha-n3 as an immunomodulator in subjects with asymptomatic HIV-1 infection. The primary endpoints of the study will include an increase or upregulation in genes known to be mediators of the natural immune response using cutting edge gene chip technology. Secondary endpoints will include the absolute CD4 count and plasma HIV RNA levels.
In December 2003 the Company announced its manufacturing agreement with Aplicare for Alferon LDO(R). To date, over 100,000 sachets of Alferon LDO(R) are available for use in the study.
Study Design
The study will be an open-label, randomized outpatient study in asymptomatic HIV infected subjects using a range of doses of interferon. Patients will be randomized to receive Alferon LDO(R) in a buffer solution once each day for 10 consecutive days at different doses. The subjects will be randomly assigned to each dose level. Clinical symptoms and adverse events will be evaluated and gene chip microarray analysis evaluations will be made in conjunction with laboratories at Vanderbilt University. The overall duration of the study, in which 60 patients are to be enrolled, will be 6 weeks.
About Alferon LDO and Potential Public Health Enhancement in
Developing Nations
Oral interferon is an experimental immunotherapeutic believed to work by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster an immune response through the entire body orally. Oral interferon would be much more economically feasible for patients and logistically manageable in development programs in third-world countries primarily affected by the this and other emerging viruses (SARS, Ebola, bird flu, etc.). Oral administration of Alferon N(R), with its affordability, low toxicity, no production of antibodies, and broad range of potential bio activity, could be a breakthrough treatment for viral diseases.
About Hemispherx and Public Health
Mentioned Last Change
HEB 3.99 0.09dollars or (2.30%)
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon N(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N(R)) and GMP certified manufacturing facilities for its novel pharma products. Hemispherx is committed to clinical development in developing nations. This commitment stems from the vast market size of the untreated patient (approx. 35 Million) and the unique biochemical property (in vitro studies) of Alferon N(R), making this high potency product worthy of this study. A number of the in vitro potency studies have been conducted at Walter Reed National Army Medical Center and published in peer reviewed medical literature. For more information please visit www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R) and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications including SARS. The Alferon(R) asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.
CONTACT: Hemispherx
Investor Relations:
Dianne Will, 518-398-6222
ir@hemispherx.net
www.hemispherx.net
Die Weicheier verkaufen und die , die wissen was läuft kaufen.....
Sagt mal wie kann man nur so........sein
Es wird beschlossen das IFSC das Medi an HEB verkauft.
Falls Ihr aber nicht wissen solltet was das heisst:
Heb hat Kurspotential bis xx Dollar. IFSC bekommt von Heb über 1,x Millionen Aktien....das bedeutet das der Cashwert von IFSC weit über 10 MillDollar liegen wird.
Bei 20 Millionen Shares von IFSC bedeutet das einen 2 stelligen Kurs...ach ja Heb hat bereits alle Schulden von IFSC bezahlt und übernimmt auch die restlichen Kosten was Miete, Strom.....ect.betrifft.
Es kommt aber noch besser: Es wurde ein 3 jähriger Vertrieb des Medikamentes von IFSC durch Heb vereinbart. IFSC bekommt davon 6% vom Netto....und nach 3 Jahren ist das Medi wieder bei IFSC.
Diese Vereinbarung des verkaufs an Heb ist nur 3 Jahre gültig....Hallo ....
ich kann nur sagen : Jetzt oder nie........
IHR WERDET ES BEREUEN
Sagt mal wie kann man nur so........sein
Es wird beschlossen das IFSC das Medi an HEB verkauft.
Falls Ihr aber nicht wissen solltet was das heisst:
Heb hat Kurspotential bis xx Dollar. IFSC bekommt von Heb über 1,x Millionen Aktien....das bedeutet das der Cashwert von IFSC weit über 10 MillDollar liegen wird.
Bei 20 Millionen Shares von IFSC bedeutet das einen 2 stelligen Kurs...ach ja Heb hat bereits alle Schulden von IFSC bezahlt
und übernimmt auch die restlichen Kosten was Miete, Strom.....ect.betrifft.Es kommt aber noch besser: Es wurde ein 3 jähriger Vertrieb des Medikamentes von IFSC durch Heb vereinbart. IFSC bekommt davon 6% vom Netto....und nach 3 Jahren ist das Medi wieder bei IFSC.
Diese Vereinbarung des verkaufs an Heb ist nur 3 Jahre gültig....Hallo ....
ich kann nur sagen : Jetzt oder nie........
IHR WERDET ES BEREUEN
Trading Spotlight
Hey Doc......
Schön das du wieder da bist.
Jetzt ist es Zeit....noch 2 Handelstage und es verkauft niemand mehr. Ich nehme an das gestern getestet wurde wo die Stopps liegen.
NEWS in Sicht...AM 9.März wird entschieden.
Datum des Gerichtes ist heute nach Börsenschluss abgelaufen Es wurden keine Einwände veröffentlicht was den Deal betreffen könnte
Jetzt gibt es nur noch : Hopp oder Topp
Look at the Bid and Ask......Ich denke das ist pure Absicht Gestern lächerliche 100K..
Ich war auch unter den Käufern Da musste ich einfach zuschlagen.
Schönes Wochenende
Schön das du wieder da bist.
Jetzt ist es Zeit....noch 2 Handelstage und es verkauft niemand mehr. Ich nehme an das gestern getestet wurde wo die Stopps liegen.
NEWS in Sicht...AM 9.März wird entschieden.
Datum des Gerichtes ist heute nach Börsenschluss abgelaufen
Es wurden keine Einwände veröffentlicht was den Deal betreffen könnteJetzt gibt es nur noch : Hopp oder Topp
Look at the Bid and Ask......Ich denke das ist pure Absicht
Gestern lächerliche 100K..Ich war auch unter den Käufern
Da musste ich einfach zuschlagen.Schönes Wochenende
Ich wusste es ..... Stopp loss......
50%
Stopp loss...... 50%
Dann warten wir mal - im Sommer brauch ich ein neues Auto... bis dahin muss die Katze im Sack sein!
Ist denn morgen schon Weihnachten???????? Aktionärsversammlung bei Ifsc
4,3K na ja bei 0,07
Es wird schon....Bis morgen
Es wird schon....Bis morgen
Wer ist denn nun investiert? Gibt es überhaupt jemanden ?
Ok 2 kenne ich bereits
Heb ist auch am steigen Morgen sehen wir die 0,10
Grüsse
Ok 2 kenne ich bereits
Heb ist auch am steigen
Morgen sehen wir die 0,10 Grüsse
Dear Interferon Sciences, Inc. Stockholder:
You are cordially invited to attend a special meeting of stockholders of Interferon Sciences, Inc. to be held on March 9, 2004 at 10:00 a.m. local time at 783 Jersey Avenue, New Brunswick, New Jersey 08901. At the special meeting, pursuant to the provisions of the Delaware General Corporation Law, ISI is seeking your approval of the sale of substantially all of our assets to Hemispherx Biopharma, Inc. ("HEB"), as described in the Asset Purchase Agreement (Annex A to this Proxy Statement). Under the Asset Purchase Agreement, ISI will receive 487,028 shares of HEB common stock (which, based upon the closing price of HEB common stock on February 6, 2004, had a value of $1,909,150).
You are cordially invited to attend a special meeting of stockholders of Interferon Sciences, Inc. to be held on March 9, 2004 at 10:00 a.m. local time at 783 Jersey Avenue, New Brunswick, New Jersey 08901. At the special meeting, pursuant to the provisions of the Delaware General Corporation Law, ISI is seeking your approval of the sale of substantially all of our assets to Hemispherx Biopharma, Inc. ("HEB"), as described in the Asset Purchase Agreement (Annex A to this Proxy Statement). Under the Asset Purchase Agreement, ISI will receive 487,028 shares of HEB common stock (which, based upon the closing price of HEB common stock on February 6, 2004, had a value of $1,909,150).
Der Hammer
Lest Euch mal ganz genau ALles durch und dann schliest selber Rückschlüsse...........
Kennt jeder
Company News and Press Releases From Other Sources:
INTERFERON SCIENCES INC files Form DEF 14A, Definitive Proxy Statement
_________________________________________________________
What Does ISI Intend To Do With The Proceeds Generated From The Sale Of HEB Common Stock?
The proceeds generated from the sale of the HEB common stock will be used to repay ISI`s creditors and, assuming ISI completes the transaction described below of which there can be no assurance, to fund the operations of Amphioxus Cell Technologies, Inc. ("ACT"), a biotechnology company that applies liver biology solutions to problems in drug discovery and human therapeutics. On October 17, 2003, ISI and ACT entered into a non-binding letter of intent pursuant to which ISI (or a subsidiary of ISI) will acquire ACT. The shareholders of ACT will receive preferred stock (the "ACT Preferred Stock") of ISI, convertible into a number of common shares of ISI equal to 75% of the fully diluted capitalization of ISI.
Based upon the outstanding and potential litigation between ISI and HEB described under the captions "Business of ISI - Legal Proceedings" and "Business of HEB - Legal Proceedings of HEB" and the general uncertainty of the current situation with HEB, ISI and ACT have decided not to continue proceeding with a potential transaction unless and until such situation is resolved in a manner that is acceptable to ACT and ISI. In addition, as of the date hereof, neither ACT nor ISI has completed its due diligence and ISI has not received the financial statements of ACT. At such time, if any, that ISI and ACT continue proceeding with a potential transaction, the due diligence process and the evaluation of the financial information will generate issues to be negotiated by the parties, including without limitation the form of any potential transaction and the representation and warranties, conditions to closing, and indemnifications contained in the form of documentation to be utilized in any potential transaction between the parties. There will be no transaction unless all such issues are successfully resolved by the parties, and there can be no assurance that the parties will be able to resolve all such issues. Therefore, ISI does not believe the potential transaction between ISI and ACT is probable of completion at the present time.
Und jetzt kommts
About Amphioxus Cell Technologies
Amphioxus Cell Technologies, Inc. is a Houston-based company that makes liver biology available to the medical marketplace. Founded in 1995, Amphioxus specializes in cultured human liver cell lines with products for high throughput ADME/Tox screening, predictive toxicology, and plasma protein production. Information about Amphioxus is available on the Web at http://www.piercenet.com.
Schaut Euch mal die HP von diesem http://www.piercenet.com.
ganz genau an...........
# # #
For more information contact:
Theodore DeFrank, Pierce
+1 815 968 0747
ted.defrank@piercenet.com
Norman Sussman, Amphioxus Cell Technologies
+1 281 679 7900 X 11
budus@amphioxus.com
Ich werde wohl nie mehr verkaufen..........
Grüsse
Lest Euch mal ganz genau ALles durch und dann schliest selber Rückschlüsse...........
Kennt jeder
Company News and Press Releases From Other Sources:
INTERFERON SCIENCES INC files Form DEF 14A, Definitive Proxy Statement
_________________________________________________________
What Does ISI Intend To Do With The Proceeds Generated From The Sale Of HEB Common Stock? The proceeds generated from the sale of the HEB common stock will be used to repay ISI`s creditors and, assuming ISI completes the transaction described below of which there can be no assurance, to fund the operations of Amphioxus Cell Technologies, Inc. ("ACT"), a biotechnology company that applies liver biology solutions to problems in drug discovery and human therapeutics. On October 17, 2003, ISI and ACT entered into a non-binding letter of intent pursuant to which ISI (or a subsidiary of ISI) will acquire ACT. The shareholders of ACT will receive preferred stock (the "ACT Preferred Stock") of ISI, convertible into a number of common shares of ISI equal to 75% of the fully diluted capitalization of ISI.
Based upon the outstanding and potential litigation between ISI and HEB described under the captions "Business of ISI - Legal Proceedings" and "Business of HEB - Legal Proceedings of HEB" and the general uncertainty of the current situation with HEB, ISI and ACT have decided not to continue proceeding with a potential transaction unless and until such situation is resolved in a manner that is acceptable to ACT and ISI. In addition, as of the date hereof, neither ACT nor ISI has completed its due diligence and ISI has not received the financial statements of ACT. At such time, if any, that ISI and ACT continue proceeding with a potential transaction, the due diligence process and the evaluation of the financial information will generate issues to be negotiated by the parties, including without limitation the form of any potential transaction and the representation and warranties, conditions to closing, and indemnifications contained in the form of documentation to be utilized in any potential transaction between the parties. There will be no transaction unless all such issues are successfully resolved by the parties, and there can be no assurance that the parties will be able to resolve all such issues. Therefore, ISI does not believe the potential transaction between ISI and ACT is probable of completion at the present time.
Und jetzt kommts
About Amphioxus Cell Technologies
Amphioxus Cell Technologies, Inc. is a Houston-based company that makes liver biology available to the medical marketplace. Founded in 1995, Amphioxus specializes in cultured human liver cell lines with products for high throughput ADME/Tox screening, predictive toxicology, and plasma protein production. Information about Amphioxus is available on the Web at http://www.piercenet.com.
Schaut Euch mal die HP von diesem http://www.piercenet.com.
ganz genau an...........
# # #
For more information contact:
Theodore DeFrank, Pierce
+1 815 968 0747
ted.defrank@piercenet.com
Norman Sussman, Amphioxus Cell Technologies
+1 281 679 7900 X 11
budus@amphioxus.com
Ich werde wohl nie mehr verkaufen..........
Grüsse
Sie sind da .............News...........................
On March 9, 2004 ISI`s stockholders approved the second asset acquisition.
Wer interesse hat und den Link möchte wo alles drinsteht der schicke mir bitte eine Nachricht in mein Postfach
Grüsse
On March 9, 2004 ISI`s stockholders approved the second asset acquisition. Wer interesse hat und den Link möchte wo alles drinsteht der schicke mir bitte eine Nachricht in mein Postfach
Grüsse
Datum der Veröffentlichung: Mar 12 2004 6:31PM ET
Also nach Börsenschluss
Mal sehen was am Montag passiert
Aktuell
BID 0,041 - ASK 0,19
Schönen Sonntag
Also nach Börsenschluss
Mal sehen was am Montag passiert
Aktuell
BID 0,041 - ASK 0,19
Schönen Sonntag
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 267 | ||
| 80 | ||
| 75 | ||
| 59 | ||
| 51 | ||
| 47 | ||
| 46 | ||
| 41 | ||
| 41 | ||
| 38 |
| Wertpapier | Beiträge | |
|---|---|---|
| 34 | ||
| 34 | ||
| 32 | ||
| 31 | ||
| 30 | ||
| 25 | ||
| 23 | ||
| 20 | ||
| 19 | ||
| 19 |
